Inventor · disambiguated record
Jijie Gu
Also filed as: GU JIJIE
19 granted patents·37 pending applications·379 citations·filing 2000–2025
95Inventor score
Top patents by PatentIndex Score
56 records- 0196US8822645B2Prostaglandin E2 dual variable domain immunoglobulins and uses thereofGHAYUR TARIQ·Filed 2009·Granted Sep 2, 2014·129 cites·39 claims
- 0296US8722855B2Dual variable domain immunoglobulins and uses thereofGHAYUR TARIQ·Filed 2010·Granted May 13, 2014·120 cites·24 claims
- 0393US9469689B2Therapeutic DLL4 binding proteinsABBVIE INC·Filed 2015·Granted Oct 18, 2016·9 cites·39 claims
- 0490US9132190B2Therapeutic DLL4 binding proteinsABBVIE INC·Filed 2013·Granted Sep 15, 2015·13 cites·46 claims
- 0590US8323651B2Antibodies to receptor of advanced glycation end products (RAGE) and uses thereofGU JIJIE·Filed 2009·Granted Dec 4, 2012·29 cites·12 claims
- 0689US9856319B2Monovalent binding proteinsABBVIE INC·Filed 2013·Granted Jan 2, 2018·8 cites·7 claims
- 0789US9045551B2Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereofABBVIE INC·Filed 2014·Granted Jun 2, 2015·12 cites·11 claims
- 0888US9115195B2Therapeutic DLL4 binding proteinsCHEN MING-JIU·Filed 2011·Granted Aug 25, 2015·13 cites·91 claims
- 0988US8623358B2Therapeutic DLL4 binding proteinsBENATUIL LORENZO·Filed 2010·Granted Jan 7, 2014·13 cites·44 claims
- 1085US9550986B2High-throughput antibody humanizationABBVIE INC·Filed 2013·Granted Jan 24, 2017·4 cites·14 claims
- 1185US8987418B2Dual specific binding proteins directed against IL-1β and/or IL-17ABBVIE INC·Filed 2014·Granted Mar 24, 2015·8 cites·28 claims
- 1284US9944720B2Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereofABBVIE INC·Filed 2015·Granted Apr 17, 2018·4 cites·13 claims
- 1383US9062108B2Dual specific binding proteins directed against IL-1 and/or IL-17ABBVIE INC·Filed 2014·Granted Jun 23, 2015·6 cites·34 claims
- 1481US9163093B2Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereofGU JIJIE·Filed 2013·Granted Oct 20, 2015·5 cites·18 claims
- 1580US9469688B2Therapeutic DLL4 binding proteinsABBVIE INC·Filed 2015·Granted Oct 18, 2016·2 cites·37 claims
- 1676US2022403052A1Anti-dll4/vegf dual variable domain immmunoglobulin and uses thereofABBVIE INC·Filed 2022·Application pending·0 cites
- 1773US9840554B2Antibodies against platelet-derived growth factor (PDGF)ABBVIE INC·Filed 2016·Granted Dec 12, 2017·2 cites·9 claims
- 1870US11970543B2Anti-CD39 antibodies and use thereofARCUS BIOSCIENCES INC·Filed 2023·Granted Apr 30, 2024·0 cites·13 claims
- 1969US9394363B2Antibodies to receptor of advanced glycation end products (RAGE) and uses thereofABBVIE DEUTSCHLAND·Filed 2012·Granted Jul 19, 2016·1 cites·10 claims
- 2068US2025084178A1Anti-cd39 antibodies and use thereofARCUS BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 2166US6831155B2Inhibition of p53 degradationHARVARD COLLEGE·Filed 2000·Granted Dec 14, 2004·1 cites·7 claims
- 2266US2010087436A1Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejectionABBOTT LAB·Filed 2009·Application pending·0 cites
- 2365US2025313633A1Anti-B7H3 antibody and Uses thereofWUXI BIOLOGICS IRELAND LTD·Filed 2023·Application pending·0 cites
- 2465US2020255508A1Therapeutic DLL4 Binding ProteinsABBVIE INC·Filed 2019·Application pending·0 cites
- 2562US2025145679A1Heterodimeric polypeptide complexes comprising il-15 variants and uses thereofWUXI BIOLOGICS IRELAND LTD·Filed 2023·Application pending·0 cites
- 2661US2025000946A1Il-2 variants and fusion proteins thereofWUXI BIOLOGICS IRELAND LTD·Filed 2022·Application pending·0 cites
- 2760US2024285685A1Genetically modified nk cells and uses thereofWUXI BIOLOGICS IRELAND LTD·Filed 2022·Application pending·0 cites
- 2860US2019031783A1Anti-dll4/vegf dual variable domain immunoglobulin and uses thereofABBVIE INC·Filed 2018·Application pending·0 cites
- 2959US2025026833A1A bispecific anti-pd-l1/vegf antibody and uses thereofWUXI BIOLOGICS IRELAND LTD·Filed 2022·Application pending·0 cites
- 3059US2018371071A1Therapeutic DLL4 Binding ProteinsABBVIE INC·Filed 2017·Application pending·0 cites
- 3158US2024317872A1Polypeptide complexes with improved stability and expressionWUXI BIOLOGICS IRELAND LTD·Filed 2022·Application pending·0 cites
- 3256US2025215109A1Anti-her2/anti-cd47 molecules and uses thereofWUXI BIOLOGICS IRELAND LTD·Filed 2023·Application pending·0 cites
- 3355US2025277054A1Psma antibodies and uses thereofWUXI BIOLOGICS IRELAND LTD·Filed 2025·Application pending·0 cites
- 3455US2024376194A1D3-binding molecules and uses thereofWUXI BIOLOGICS IRELAND LTD·Filed 2022·Application pending·0 cites
- 3555US2024076411A1Multispecific antigen binding proteinsWUXI BIOLOGICS IRELAND LTD·Filed 2021·Application pending·0 cites
- 3655US2023391846A1Modified soluble t cell receptorWUXI BIOLOGICS IRELAND LTD·Filed 2021·Application pending·0 cites
- 3754US2023270823A1Long-acting il-15 and uses thereofWUXI BIOLOGICS IRELAND LTD·Filed 2021·Application pending·0 cites
- 3853US2015017095A1Prostaglandin e2 dual variable domain immunoglobulins and uses thereofABBVIE INC·Filed 2014·Application pending·0 cites
- 3952US2023072133A1A bifunctional fusion protein and uses thereofWUXI BIOLOGICS IRELAND LTD·Filed 2021·Application pending·0 cites
- 4052US2013243789A1Multiple Gene Expression Including sORF Constructs and Methods with Polyproteins, Pro-Proteins and ProteolysisCARSON GERALD R·Filed 2013·Application pending·0 cites
- 4152US2007065912A1Multiple Gene Expression including sORF Constructs and Methods with Polyproteins, Pro-Proteins, and ProteolysisABBOTT LAB·Filed 2006·Application pending·0 cites
- 4251US2014308286A1Dual variable domain immunoglobulins and uses thereofABBVIE INC·Filed 2014·Application pending·0 cites
- 4349US2016319026A1Dual variable domain immunoglobulins and uses thereofABBVIE INC·Filed 2016·Application pending·0 cites
- 4449US2011034368A1Multiple Gene Expression Including sORF Constructs and Methods with Polyproteins, Pro-Proteins and ProteolysisABBOTT LAB·Filed 2010·Application pending·0 cites
- 4549US2013195871A1Dual variable domain immunoglobulins and uses thereofGHAYUR TARIQ·Filed 2012·Application pending·0 cites
- 4648US2016175316A1Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejectionABBVIE INC·Filed 2015·Application pending·0 cites
- 4748US2017002075A1Antibodies to receptor of advanced glycation end products (rage) and uses thereofABBVIE DEUTSCHLAND·Filed 2016·Application pending·0 cites
- 4848US2014235476A1Multivalent binding protein compositions and methods for identifying variants of sameABBVIE INC·Filed 2013·Application pending·0 cites
- 4948US2014186377A1Prostaglandin e2 binding proteins and uses thereofABBVIE INC·Filed 2013·Application pending·0 cites
- 5047US2014213772A1Cross-over dual variable domain immunoglobulin constructsABBVIE INC·Filed 2013·Application pending·0 cites
Showing the top 50 of 56 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Jijie Gu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →